Using STAT3 and SMAD2/3 reporter neuroblastoma cells, we showed that reporter activity was inhibited when treatment with lenalidomide was begun 72 h after injection of tumor cells into NOD/SCID mice, which suggest that lenalidomide may block ongoing phosphorylation and so contribute to a decrease in the level of activation. This evidence concerns the gene STAT3 and neuroblastoma.